Stay updated on Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Sign up to get notified when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.

Latest updates to the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedMinor wording change in the Publications section (about the results of the study vs about the study results) and an adjacent revision tag update (v3.3.2 vs v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check27 days agoChange DetectedThe government funding notice about potential delays and NIH operating status has been removed from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedTwo screenshots show only cosmetic UI adjustments and a loading overlay. Core trial details such as title, condition, interventions, outcomes, enrollment, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check71 days agoChange DetectedReleased v3.2.0 with a new operating-status notice for the NIH Clinical Center and links to status sources; old v3.1.0 version removed.SummaryDifference1%

- Check78 days agoChange DetectedUpdated page version to v3.1.0 and removed several drug-safety related topics, indicating a reorganization/pruning of content rather than new substantive information.SummaryDifference0.2%

- Check92 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1; the Back to Top element was removed (minor UI change).SummaryDifference0.1%

Stay in the know with updates to Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Semaglutide Once-weekly vs Placebo add-on to SGLT-2i in T2DM Clinical Trial page.